| Conţinutul numărului revistei |
| Articolul precedent |
| Articolul urmator |
 |
 354 1 |
| Ultima descărcare din IBN: 2023-10-26 12:09 |
| Căutarea după subiecte similare conform CZU |
| 617.753.2-085.216.84 (1) |
| Științe medicale. Medicină (11483) |
 SM ISO690:2012РОСТЕЛЬ, Виктория, НЕВСКАЯ, Алла, ЗАДОРОЖНЫЙ, О., КОРОЛЬ, А.. Сравнение эффективности афлиберцепта и ранибизумаба при миопических субретинальных неоваскулярных мембранах. Исследование COAST.UA (отчёт №1). In: Sănătate Publică, Economie şi Management în Medicină , 2022, nr. 1(92-S), pp. 94-95. ISSN 1729-8687. |
| EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
| Sănătate Publică, Economie şi Management în Medicină | ||||||
| Numărul 1(92-S) / 2022 / ISSN 1729-8687 /ISSNe 2587-3873 | ||||||
|
||||||
| CZU: 617.753.2-085.216.84 | ||||||
| Pag. 94-95 | ||||||
|
||||||
 Descarcă PDF |
||||||
| Rezumat | ||||||
The prevalence of pathological myopia is 1-3% in the adult population, of which 5-11% of cases develop subretinal neovascular membranes. The aim of this study was to compare the effectiveness of ranibizumab and aflibercept in the treatment of patients with subretinal neovascular membrane in myopia. As a result of the study, it was found that the use of ranibizumab and aflibercept similarly increased visual acuity in patients with subretinal neovascular membrane in myopia, without a significant difference in the number of intravitreal injections performed at a follow-up period of 12 months. In addition, ranibizumab and aflibercept significantly reduce the central thickness of the retina. |
||||||
| Cuvinte-cheie aflibercept, ranibizumab, subretinal neovascular membranes, афлиберцепт, ранибизумаб, субретинальные неоваскулярные мембраны |
||||||
|
|
|
|
